Background: Little is known about the epidemiology of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in children.
S tevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially life-threatening disorders characterized by widespread epidermal necrosis of skin and mucosa. Classification is based on body surface area (BSA) affected, with SJS involving less than 10%, SJS-TEN 10% to 30%, and TEN greater than 30% of BSA. 1 Incidences of SJS and TEN in the general population are reported to be 1 to 7 and 1 to 2 cases per million, respectively. [2] [3] [4] [5] Little is known about the Reports of mortality for SJS-TEN in adults are as high as 34%, [6] [7] [8] but as low 0% to 3.6% 9,10 and 0% to 7% 11, 12 in pediatric SJS and TEN, respectively. The burden of SJS and TEN in children on the health care system in terms of cost and length of stay (LOS) in the United States has not been quantified. We sought to determine risk factors, comorbidities, inpatient burden, and mortality in US children with SJS, SJS-TEN, and TEN. Sample weights were created by NIS to adjust for the complex sampling design. Cases were multiplied by weights to provide more accurate estimates for overall frequency in the United States. All data were deidentified and no attempts were made to identify individuals in the database. Patient consent was not obtained as the databases were received deidentified. All parties with access to the Healthcare Cost and Utilization Project were compliant to its formal data use agreement. The study did not require approval from the institutional review board.
METHODS

Exposures and outcomes
The databases were searched for a primary and/or secondary discharge International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 695.13, 695.14, and 695.15 corresponding to SJS, SJS-TEN, and TEN, respectively. Based on a previously validated algorithm, patients who had a LOS less than 3 days were excluded to improve positive predictive value of diagnostic codes. 13 Patients with a concomitant diagnosis of any other bullous dermatosis were excluded (ICD-9-CM: 694.0-694.9), because certain bullous dermatoses have rarely been reported to masquerade as TEN.
14 In addition, patients with a concomitant diagnosis of erythema multiforme major (ICD-9-CM: 695.12), Kawasaki disease (ICD-9-CM: 446.1), herpes simplex virus infection (ICD-9-CM: 054.XX), and Mycoplasma pneumoniae infection (ICD-9-CM: 041.81 or 483.0) were excluded. No patient had a concomitant diagnosis of graft-versus-host disease (GVHD). Newborn infants were excluded from the control group.
A comorbidity was considered present if listed as a diagnosis when the patient also had a diagnosis of SJS, SJS-TEN, or TEN. Coding of comorbidities used ICD-9-CM diagnostic codes. Comorbidities analyzed were selected based on previous associations with SJS-TEN in the literature or to explore for novel associations. Odds ratios (OR) and 95% confidence intervals (CI) were plotted on forest plots through Open Meta Analyst, an open-source software supported by Brown University and the AHRQ. ICD-9-CM codes were also used to determine procedures, including mechanical ventilation, skin grafts, dialysis, and total parenteral nutrition. Inpatient mortality was calculated. Mortality risk and loss of function were determined by the All Patient Refined Diagnoses Related Group, which includes severity of illness and risk of mortality subclasses. 15 
Statistical analysis
All data processing and statistical analyses were performed using software (SAS, Version 9.4, SAS Institute, Cary, NC). Analyses were performed using SURVEY procedures that adjusted for survey weighting, sampling clusters, and strata. Weighted incidences of a primary and/or secondary diagnosis of SJS, SJS-TEN, and TEN were determined. Calculation of incidences excluded patients who were transferred to another hospital. Costs were adjusted for inflation to the year 2014 according to the Consumer Price Index from the US Bureau of Labor Statistics. 16 Summary statistics were generated for LOS and inflation-adjusted cost of care, including sum, mean, SD, minimum, maximum, and median.
Associations of SJS-TEN, cost, LOS, and mortality were examined for the following variables: age in years, gender, race/ethnicity, median annual income of the hospital ZIP code, health insurance coverage, number of chronic conditions, season of hospitalization, hospital location, teaching status and bed size (Supplemental Table I ; available at http:// www.jaad.org), and patient disposition at discharge. Multivariate survey logistic regression models were constructed and the control group included all pediatric patients without a diagnosis of SJS, SJS-TEN, or TEN, yielding a representative cohort of hospitalized pediatric patients. To determine the predictors of inpatient mortality, multivariate logistic regression models with stepwise selection were constructed with mortality as the dependent variable. All sufficiently powered comorbidities were included in the mortality selection model. Analyses of mortality only included pediatric patients with SJS, SJS-TEN, and TEN. Logistic regression was used to compare incidence and mortality for SJS, SJS-TEN, or TEN between admission years. Complete case analysis was performed. A 2-sided P value less than .05 was considered statistically significant.
RESULTS
Overall, 1,687,172 pediatric admissions excluding healthy newborns were captured in the NIS in 2009 to 2012. Weighted frequencies, which more accurately represent the full spectrum of US hospitalizations, were 1210 and 369 for a primary and secondary diagnosis of SJS, 192 and 59 for SJS-TEN, and 64 and 65 for TEN, respectively (Table I) . Estimated frequencies per million children ranged from 4.3 to 5.8 for SJS, 0.6 to 1.4 for SJS-TEN, and 0 to 0.7 for TEN. The frequency of SJS and SJS-TEN were stable between 2009 and 2012 (P [.05). There was a significant decrease in the frequency of TEN in 2011 (P = .01). Average age was 10.5 6 0.2, 10.4 6 0.7, and 9.3 6 0.7 years for SJS, SJS-TEN, and TEN, respectively. The demographics of children with or without SJS/TEN are presented in Supplemental Table II (available at http://www.jaad.org).
The strongest shared predictor of SJS, SJS-TEN, and TEN was increasing age (linear regression; P \ .05 for all) (Supplemental Table III ; available at http://www.jaad.org). SJS and SJS-TEN were also associated with the number of chronic conditions present.
Comorbidities
In multivariate survey logistic regression models controlling for sociodemographic factors, both SJS and SJS-TEN/TEN were associated with ocular infection or inflammation 
Hospital course
The mean 6 SE LOS for patients with SJS, SJS-TEN, and TEN was 9.4 6 0.6, 15.7 6 1.5, and 20.4 6 6.3 days compared with only 4.6 6 0.1 days in children without these disorders, respectively. One in 10 children with SJS, SJS-TEN, and TEN underwent mechanical ventilation (aOR 10.8%, 95% CI 7.7-13.9) ( Table I) . Patients were most frequently routinely discharged to home or other self-care (aOR 89.5%, 95% CI 86.8-92.2%).
Cost
The mean 6 SE inflation-adjusted cost of hospitalization for children with SJS, SJS-TEN, and TEN was $24,947 6 $3171, $63,787 6 $8014, and $102,243 6 $37,588, respectively, compared with $10,496 6 $424 for the control group. The cumulative cost of care from 2009 to 2012 was $36,461,811, $15,014,602, and $11,695,400 for all patients with SJS, SJS-TEN, and TEN.
Mortality
Mortality was 0% for SJS, 4% for SJS/TEN, and 16% for TEN. Mortality for SJS-TEN or TEN did not significantly change over time (P [.05), although in 2011 there were no observed cases of childhood (Table II) .
DISCUSSION
This study found that childhood SJS, SJS-TEN, and TEN caused a significant health care burden, with a mean cost of hospitalization of [$20,000, [$50,000, and [$100,000, respectively, and a total 4-year cost of $63,001,951 (mean $16.3 million per year). Children with SJS-TEN also had up to a 4-fold longer duration and 9-fold higher mean cost of hospitalization in comparison with other pediatric admissions. The incidences of SJS, SJS-TEN, and TEN appear to be lower in US children (5.3, 0.8, and 0.4 cases per million children per year) than in adults (9.3, 1.9, and 1.6 cases per million adults per year). 6 The estimated incidence of pediatric SJS was similar to previous reports in the general population (1-7 cases per million), but slightly lower for TEN (1-2 cases per million). [2] [3] [4] [5] [6] A previous study of 37 pediatric patients with SJS-TEN calculated incidences of erythema multiforme, SJS, and TEN in patients younger than 20 years to be 7.0 per million person-years. 17 A higher number of chronic health conditions were associated with SJS and SJS-TEN, suggesting that underlying comorbidities and/or concomitant polypharmacy contribute to pediatric SJS-TEN. Eye infection/inflammation manifested in more than a third of children with SJS/TEN, within the range of previous reports of ocular involvement in SJS/TEN (18.8%-84%). 18, 19 The rate could be higher as ocular involvement in SJS/TEN may not be coded with separate International Classification of Diseases codes. Although we previously observed racial disparities in the incidence and costs of SJS/TEN in adults, these disparities were not seen in children.
Mortality in children with SJS (0%), SJS-TEN (4.0%), and TEN (16.0%) was similar to previous reports from smaller cohorts (SJS: 0%-3.6%, TEN: 0%-16.7%).
9,11,12,20 A previous study found that children J AM ACAD DERMATOL VOLUME 76, NUMBER 5 with 60% to 70% BSA had a mortality of 37.5%. 20 Thus, it appears that increasing BSA involvement correlates with increased mortality in children. In contrast, US adults with SJS-TEN and TEN had similar mortality, 6 in agreement with the SCORTEN (SCORe of Toxic Epidermal Necrosis) where BSA greater than 10% is a predictor of mortality in adults with SJS-TEN. 21 Further studies are needed to confirm whether BSA greater than 30% confers additional mortality risk than BSA of 10% to 29%.
Many children with SJS-TEN and TEN died from multiple comorbid health conditions and not their skin disease per se. Renal failure, septicemia, bacterial infection, liver damage, epilepsy, and malignancy were all associated with increased mortality in SJS-TEN and TEN. The association between mortality and renal failure is consistent with the SCORTEN (elevated serum blood urea nitrogen). The lack of association with diabetes and other disorders with elevated blood glucose is not consistent with SCORTEN. Septicemia was likely caused by impaired skin-barrier from denuded skin. Although not included in SCORTEN, infectious complications were previously found to be the most common cause of death in SJS/TEN. 22 It is also possible that antibiotics used for treatment of preceding infections may have triggered SJS-TEN. Antiepileptics are implicated as one of the most common causes of SJS-TEN and TEN, 23 although epilepsy and antiepileptics have rarely been associated with mortality.
Strengths of this study include an analysis of a nationally representative sample of all-payer data over a period of 4 years with over 4.5 million records that included several hundred cases of SJS, SJS-TEN, and TEN and using a validated algorithm for case selection. Virtually all patients present for care and are admitted to the hospital for evaluation and management and, thus, this inpatient cohort is likely sufficient to describe the epidemiology of these disorders. Limitations of our study include the inability to perform temporal analysis of comorbidities, as date of diagnosis was not documented. LOS may have been overestimated, because we excluded patients with LOS less than 3 days in our case definition. We were unable to assess medications administered preceding the diagnosis of SJS-TEN or for the treatment of SJS-TEN. Thus, we were unable to determine whether SJS-TEN is related to a particular disease or its treatment. We were also unable to analyze whether treatment affects mortality. Identification of comorbidities was performed using ICD-9-CM codes and not by review of the health record. Given that this is a deidentified national database, we were unable to verify diagnoses of SJS/ TEN. We explored for a concomitant diagnosis of hematopoietic stem cell transplantation and SJS/TEN and only found 1 patient with malignancy who received a bone-marrow transplant. There were no cases of GVHD. Severe cutaneous GVHD can be difficult to distinguish from TEN, 16, 24 and it is possible that some patients given a diagnosis of a malignancy and SJS-TEN/TEN actually had GVHD. The absence of TEN in 2011 could be attributed to sampling, as the NIS is a 20% sample of all US hospitalizations, and pediatric TEN is rare. Finally, some procedures may have been coded using Current Procedural Terminology without corresponding International Classification of Diseases codes. This could result in underestimation of the rates of procedures.
In conclusion, pediatric SJS/TEN is a substantial health burden in the United States with increased costs, LOS, and mortality. Incidences of SJS, SJS-TEN, and TEN were lower in children than observed in adults. Mortality and procedures such as ventilation and dialysis were substantially higher in TEN than in SJS or SJS-TEN, suggesting that BSA of involvement greater than 30%enot just greater than 10%eis an additional mortality risk factor. Renal failure, septicemia, and bacterial infections were the strongest predictors of mortality. Predictors of SJS, SJS-TEN, or TEN in children, presented as odds ratios based on logistic regression models controlling for sociodemographics and race and adjusting for survey weighting, sampling clusters and strata. Bold denotes a statistically significant finding. CI, Confidence interval; NE, not estimable; OR, odds ratio; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
